572 related articles for article (PubMed ID: 23380337)
21. Newer generation fentanyl transmucosal products for breakthrough pain in opioid-tolerant cancer patients.
Elsner F; Zeppetella G; Porta-Sales J; Tagarro I
Clin Drug Investig; 2011; 31(9):605-18. PubMed ID: 21819159
[TBL] [Abstract][Full Text] [Related]
22. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK
Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084
[TBL] [Abstract][Full Text] [Related]
23. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
Mercadante S; Villari P; Ferrera P; Casuccio A; Mangione S; Intravaia G
Br J Cancer; 2007 Jun; 96(12):1828-33. PubMed ID: 17519902
[TBL] [Abstract][Full Text] [Related]
24. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
Portenoy RK; Messina J; Xie F; Peppin J
Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
[TBL] [Abstract][Full Text] [Related]
25. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients.
Farrar JT; Cleary J; Rauck R; Busch M; Nordbrock E
J Natl Cancer Inst; 1998 Apr; 90(8):611-6. PubMed ID: 9554444
[TBL] [Abstract][Full Text] [Related]
26. Opioids for the management of breakthrough (episodic) pain in cancer patients.
Zeppetella G; Ribeiro MD
Cochrane Database Syst Rev; 2006 Jan; (1):CD004311. PubMed ID: 16437482
[TBL] [Abstract][Full Text] [Related]
27. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer.
Portenoy RK; Taylor D; Messina J; Tremmel L
Clin J Pain; 2006; 22(9):805-11. PubMed ID: 17057563
[TBL] [Abstract][Full Text] [Related]
28. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer.
Vissers DC; Lenre M; Tolley K; Jakobsson J; Sendersky V; Jansen JP
Value Health; 2011; 14(2):274-81. PubMed ID: 21402296
[TBL] [Abstract][Full Text] [Related]
29. Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose.
Nalamachu SR; Parikh N; Dillaha L; Rauck R
J Opioid Manag; 2014; 10(4):247-54. PubMed ID: 25162604
[TBL] [Abstract][Full Text] [Related]
30. Evidence-based treatment of cancer-related breakthrough pain with opioids.
Zeppetella G
J Natl Compr Canc Netw; 2013 Mar; 11 Suppl 1():S37-43. PubMed ID: 23520185
[TBL] [Abstract][Full Text] [Related]
31. Treating breakthrough pain in oncology.
Mercadante S
Expert Rev Anticancer Ther; 2018 May; 18(5):445-449. PubMed ID: 29478355
[TBL] [Abstract][Full Text] [Related]
32. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Masel EK; Landthaler R; Gneist M; Watzke HH
Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
[TBL] [Abstract][Full Text] [Related]
33. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
[TBL] [Abstract][Full Text] [Related]
34. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
Mercadante S
Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
[TBL] [Abstract][Full Text] [Related]
35. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
Überall MA
MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
[TBL] [Abstract][Full Text] [Related]
36. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
37. A randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries.
Mahar PJ; Rana JA; Kennedy CS; Christopher NC
Pediatr Emerg Care; 2007 Aug; 23(8):544-8. PubMed ID: 17726413
[TBL] [Abstract][Full Text] [Related]
38. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
Parikh N; Goskonda V; Chavan A; Dillaha L
Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
[TBL] [Abstract][Full Text] [Related]
39. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
[TBL] [Abstract][Full Text] [Related]
40. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
